1. Quick Heal IPO hits market: Top 10 key points to know before investing

Quick Heal IPO hits market: Top 10 key points to know before investing

Quick Heal is one of the leading providers of security software products and solutions in India with a market share of over 30 per cent in the retail segment according to the Zinnov Industry Report.

By: | Updated: February 8, 2016 1:01 PM
Narayana Hrudayalaya IPO The company has set a price band of Rs 311 to Rs 321 per equity share of face value of Rs 10 each.

Quick Heal Technologies Limited hit the capital markets with its initial public offerings (IPO) on February 8, 2016. ICICI Securities Limited, Jefferies India Private Limited, and JP Morgan India Private Limited are the book running lead managers for the issue.

Here are top 10 key takeaways you should know about Quick Heal before investing in the public offer: 

About the company: Quick Heal is one of the leading providers of security software products and solutions in India with a market share of over 30 per cent in the retail segment according to the Zinnov Industry Report. The company’s end customers include home users, small offices and home offices, enterprises, educational institutions, as well as government agencies and departments.

About the offer: The IPO consists of a fresh issue of Rs 2,500 million by the company and an offer for sale of upto 6,269,558 equity shares by promoters Kailash Sahebrao Katkar and Sanjay Sahebrao Katkar, apart from Sequoia Capital India Investment Holdings III and Sequoia Capital India Investments III. The IPO will close on February 10.

Price Band: The company has set a price band of Rs 311 to Rs 321 per equity share of face value of Rs 10 each.

Objective of the issue: While the proceeds from the offer of sale would not go to Quick Heal Technologies, the Rs 250 crore funds raised from fresh issue of equity shares would be used by the company for advertising and sales promotion and capital expenditure for research and development. The proceeds would also be invested to purchase, develop and renovate its office premises in Kolkata, Pune and New Delhi, as well as general corporate needs.

Financials: For the financial year ended March 2015, Quick Heal generated total revenue of Rs 2,94.34 crore, gross profit of Rs 2,60.62 crore, EBITDA of Rs 91.80 crore and restated profit for the year of Rs 53.80 crore. For the five fiscal years ended March 2015, the company’s total revenue, gross profit, EBITDA and restated profit grew at a CAGR of 21.94 per cent, 20.97 per cent, 13.07 per cent and 8.67 per cent, respectively.

For the financial year ended 2015, Quick Heal derived 97.31 per cent and 2.69 per cent of its revenue from sales to users within India and outside India, respectively.

Balance sheet & cash flow generation: Quick Heal has a debt-free balance sheet and cash balance of Rs 107 crore as of 1HFY2016. Over the past five years, the company is generating strong operating cash flows which have grown from Rs 49 cr in FY2012 to Rs 77 in FY2015. Angel Broking in a research note said, “We believe that the company generates sufficient cash flows to cover for R&D and technology up-gradation related expenses.”

Headcounts: As of June 30, 2015, we had 1,231 full-time employees, including 449 employees in the R&D team and 345 employees in our Sales & Marketing team.

Listing: Quick Heal’s equity shares are proposed to be listed on the BSE and the NSE.

Outlook: According to SMC Investment and Advisors, Quick Heal enjoys preferred anti-virus solution provider company status with a market share of 30 per cent in the domestic market. It hopes to increase its substantially as its products have been receiving approval from world renowned agencies. In the RHP, there are no listed peers to compare with and thus this issue is also from the first mover of the segment and may create fancy, but it cannot be denied that the issue price looks expensive. An investor can opt the issue for long term investment.

Angel Broking recommends a ‘Subscribe’ on the issue from a longer term perspective.

Valuation: According to SMC, considering the P/E valuation on the upper end of the price band of Rs 321, the stock is priced at pre issue P/E of 41.24x on its FY16 EPS of Rs 7.78. Post issue, the stock is priced at a P/E of 46.41 x on its EPS of Rs 6.92. Looking at the P/B ratio at Rs 321 the stock is priced at P/B ratio of 5.26x on the pre issue book value of Rs 61.06 and on the post issue book value of Rs 89.96 the P/B comes out to 3.57x.

  1. No Comments.

Go to Top